Diag2Tec was founded in June 2015, by 5 associates (Jérôme Moreaux, Jean-Luc Veyrune, Alboukadel Kassambara, Angélique Bruyer and Pierre Vidal).
Diag2tec relies a strong scientific expertise of the hospital laboratory of the monitoring Innovative Therapies (Montpellier University Hospital) and of the Academic Research team (CNRS UPR1142- ex INSERM U1040).
- The hospital laboratory is in charge of phenotypic and molecular diagnosis and residual disease monitoring of MM patients and this diagnostic activity is associated with the Biological Resources Center and the Department for Clinical Hematology (Pr Guillaume Cartron) of the Montpellier University Hospital).
- The research team has joined the group of Philippe Pasero at the Institute of Human Genetics in January 2015 and is involved in the studie of MM physiopathology since 20 years. The team is collaborating with the German Myeloma group (Pr Goldschmidt’s team, Heidelberg) since 2003 and has accumulated gene expression profiling of tumor cells of 300 patients at diagnosis, with a careful patients’ follow-up, in particular response rate, event free survival and overall survival.
- Jérôme Moreaux is the successor of Bernard Klein to lead the hospital and research activity of the group with the biological and technical resources accumulated over two decades of research about Multiple Myeloma.
The strength of Diag2Tec lies in the complementary skills of each founders and member of Scientific Advisor Board and in the long and recognized experience of the scientific team in MM research, diagnosis and biological follow-up of patients.